These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11146378)

  • 21. Perspective: genetic and hormonal roles in bone disorders: insights of an updated bone physiology.
    Frost HM
    J Musculoskelet Neuronal Interact; 2003 Jun; 3(2):118-35. PubMed ID: 15758352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why do bone strength and "mass" in aging adults become unresponsive to vigorous exercise? Insights of the Utah paradigm.
    Frost HM
    J Bone Miner Metab; 1999; 17(2):90-7. PubMed ID: 10340635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
    Riggs BL; Parfitt AM
    J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the pathogenesis of osteogenesis imperfecta: some insights of the Utah paradigm of skeletal physiology.
    Frost HM
    J Musculoskelet Neuronal Interact; 2003 Mar; 3(1):1-7. PubMed ID: 15758360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoporosis and the growth hormone-insulin-like growth factor axis.
    Geusens PP; Boonen S
    Horm Res; 2002; 58 Suppl 3():49-55. PubMed ID: 12435898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of growth hormone on skeletal muscle.
    Weber MM
    Horm Res; 2002; 58 Suppl 3():43-8. PubMed ID: 12435897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone and bone.
    Ohlsson C; Bengtsson BA; Isaksson OG; Andreassen TT; Slootweg MC
    Endocr Rev; 1998 Feb; 19(1):55-79. PubMed ID: 9494780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anabolic processes in human skeletal muscle: restoring the identities of growth hormone and testosterone.
    West DW; Phillips SM
    Phys Sportsmed; 2010 Oct; 38(3):97-104. PubMed ID: 20959702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of growth hormone replacement therapy on bone metabolism].
    Yamamoto M; Sugimoto T
    Clin Calcium; 2014 Jun; 24(6):903-9. PubMed ID: 24870842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal growth and peak bone strength.
    Wang Q; Seeman E
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):687-700. PubMed ID: 19028352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skeletal consequences of discontinuation of growth hormone at final height.
    Drake WM; Carroll PV; Savage MO; Monson JP
    J Pediatr Endocrinol Metab; 2002 Dec; 15 Suppl 5():1351-4. PubMed ID: 12510990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis.
    Gillberg P; Mallmin H; Petrén-Mallmin M; Ljunghall S; Nilsson AG
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4900-6. PubMed ID: 12414848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bone and hormones. Effects of growth hormone on bone tissue in adults].
    Chapurlat RD; Delmas PD
    Presse Med; 1999 Mar; 28(10):559-62. PubMed ID: 10209550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity, and bone strength and "mass": a tutorial based on insights from a new paradigm.
    Frost HM
    Bone; 1997 Sep; 21(3):211-4. PubMed ID: 9276084
    [No Abstract]   [Full Text] [Related]  

  • 38. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men.
    Johansson AG; Eriksen EF; Lindh E; Langdahl B; Blum WF; Lindahl A; Ljunggren O; Ljunghall S
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2795-8. PubMed ID: 9284698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Osteoporosis a disease requiring treatment or a physiologic osteopenia state? WHO definition in opposition to Utah Paradigm?].
    Frost HM; Schneider P; Schneider R
    Dtsch Med Wochenschr; 2002 Nov; 127(48):2570-4. PubMed ID: 12457328
    [No Abstract]   [Full Text] [Related]  

  • 40. [Bone histomorphometry;A role of evaluation for bone quality and mechanical strength].
    Yamamoto N; Takahashi H; Shimakura T
    Clin Calcium; 2016 Jan; 26(1):9-15. PubMed ID: 26728526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.